• Bozzelli PL, Yin T, Avdoshina V, Mocchetti I, Conant KE, Maguire-Zeiss KA. HIV-1 Tat promotes astrocytic release of CCL2 through MMP/PAR-1 signalingGlia. 2019 Sep;67(9):1719-1729. doi: 10.1002/glia.23642. Epub 2019 May 23.

  • Caplan, I. F., & Maguire-Zeiss, K. A. (2018). Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies. Frontiers in Pharmacology9, 417.
  • Conant K, Daniele S, Bozzelli PL, Abdi T, Edwards A, Szlarczyk A, Olchefske I, Ottenheimer D, and Maguire-Zeiss K. (2017) Matrix metalloproteinase activity stimulates N-cadherin shedding and the soluble N-cadherin ectodomain promotes classical microglial activation. J Neuroinflammation, 12:56.
  • Allen M, Ghosh S, Ahern GP, Villapol S, Maguire-Zeiss KA, and Conant K. (2016) Protease induced plasticity: matrix metalloproteinase-1 promotes neurostructural changes through activation of protease activated receptor 1. Sci Rep., 2016, 6:35497.
  • Daniele SG, Beraud D, Davenport C, Cheng K, Yin H, and Maguire-Zeiss KA. (2015) Activation of MyD88-dependent TLR1/2 signaling by misfolded a-synuclein, a protein linked to neurodegenerative disorders. Science Signaling, 12 May 2015; vol 8, Issue 376, p. ra45; DOI:10.1126/scisignal.2005965
  • Daniele SG,  G, Edwards AA and Maguire-Zeiss KA (2014) Efficient isolation of cortical microglia with preserved immunophenotype and functionality from murine neonates. Journal of Visualized Experiments (2014) Jan 30;(83):e510005.
  • Beraud D,  D, Hathaway HA, Trecki J, Chasovskikh S, Johnson DA, Johnson JA, Federoff HJ, Shimoji M, Mhyre TR and Maguire-Zeiss KA (2013) Microglial activation and antioxidant responses induced by the Parkinson’s disease protein a-synuclein. Journal of Neuroimmune Pharmacology Mar;8(1):94-117; PMCID:PMC3582877     
  • Conant K, Lim ST, Randell B and Maguire-Zeiss KA (2012) Matrix metalloproteinase dependent cleavage of cell adhesion molecules in the pathogenesis of CNS dysfunction with HIV and methamphetamine. Current HIV Res. 10(5):384-91;PMCID pending; NIHMS 432503.
  • Beraud D and Maguire-Zeiss KA (2012) Misfolded alpha-synuclein and toll-like receptors: therapeutic targets for Parkinson’s disease. Parkinsonism Relat Disord. 18 Suppl 1:S17-20.
  • Feng LR and Maguire-Zeiss KA (2011) Dopamine and paraquat enhance alpha-synuclein-induced alterations in membrane conductance. Neurotoxicity Research,  20(4):387-401.
  • Beraud D, Twomey M, Bloom B, Mittereder A, Neitzke, Ton V, Chasovskikh S, Mhyre T and Maguire-Zeiss KA (2011) Alpha-synuclein alters Toll-like receptor expression. Frontiers in Neurodegeneration, 5, Article 80:1-11.
  • Conant K, Lonskaya I, Szklarczyk A, Krall C, Steiner J, Maguire-Zeiss K and Lim ST (2011) Methamphetamine associated cleavage of the synaptic adhesion molecule ICAM-5. J Neurochem. 118(4):521-32.
  • Maguire-Zeiss KA and Federoff HJ. (2010) Future directions for immune modulation in neurodegenerative disorders:focus on Parkinson’s disease. J Neural Transm. 2010 Aug;117(8):1019-25.
  • Feng LR and Maguire-Zeiss KA. (2010) Gene Therapy in Parkinsons Disease: Rationale and Current Status. CNS Drugs, Leading Article, 24(3):177-266; PMC-In Process.
  • Lee BD, Shin JH, VanKampen J, Petrucelli L, West AB, Ko HS, Lee YI, Maguire-Zeiss KA, Bowers WJ, Federoff HJ, Dawson VL and Dawson TM (2010) Inhibitors of leucine rich repeat kinase 2 (LRRK2) protect against LRRK2-models of Parkinson's disease Nature Medicine, 2010 Sep;16(9):998-1000.
  • Feng LR, Federoff HJ, Vicini S and Maguire-Zeiss KA (2010) Alpha-synuclein mediates alterations in membrane conductance: a potential role for alpha-synuclein oligomers in cell vulnerability. European Journal of Neuroscience, 32:10-17; PMCID: PMC2900531.